Revance Releases Third Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Revance Releases Third Quarter 2018 Results

Revance Therapeutic (RVNC) PT Lowered to $42 at Mizuho Securities

November 2, 2018 7:25 AM EDT

Mizuho Securities analyst, Difei Yang, lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $48.00) while maintaining a Buy rating following the company's 3Q earnings report. Revance reported 3Q EPS of $(0.91) that is slightly above FactSet consensus of $(0.92). $2.4 mil of revenue was... More

Revance Therapeutics (RVNC) Tops Q3 EPS by 6c

November 1, 2018 4:58 PM EDT

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.91), $0.06 better than the analyst estimate of ($0.97).

"We look forward to an impactful fourth quarter," said Dan Browne, president and chief executive officer at Revance. "In addition to the initiation of two new Phase 2... More